According to current practice highlighted in this video, which biomarker panel is now considered essential for optimal first-line treatment selection in advanced gastric cancer?
HER2, MSI/dMMR, PD-L1, and CLDN18.2—representing the full spectrum of actionable targets to guide personalized therapy selection
HER2, EGFR, BRAF, and KRAS—mirroring the colorectal cancer biomarker paradigm for precision oncology
PD-L1, TMB, and NTRK—focusing exclusively on immunotherapy and fusion-driven targets